Breast and ovarian cancer cells harboring BRCA1 mutations are sensitive to DNA damaging agents and radiation therapy, highlighting the critical role of BRCA1 in response to DNA damaging agents [35], [36]. This evidence concerns the gene BRCA1 and ovarian carcinoma.